AbbVie
ABBV
4,115 hedge funds and large institutions have $282B invested in AbbVie in 2026 Q1 according to their latest regulatory filings, with 192 funds opening new positions, 1,735 increasing their positions, 1,719 reducing their positions, and 182 closing their positions.
5% more first-time investments, than exits
New positions opened: 192 | Existing positions closed: 182
1% more repeat investments, than reductions
Existing positions increased: 1,735 | Existing positions reduced: 1,719
1.19% less ownership
Funds ownership: 74.6% → 73.41% (-1.2%)
1% less funds holding
Funds holding: 4,169 → 4,115 (-54)
6% less capital invested
Capital invested by funds: $301B → $282B (-$19.1B)
11% less call options, than puts
Call options by funds: $2.21B | Put options by funds: $2.5B
13% less funds holding in top 10
Funds holding in top 10: 200 → 175 (-25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$1.88B |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.3B |
| 3 |
JP Morgan Chase
New York
|
+$965M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$782M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$705M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$2.71B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.78B |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$1.74B |
| 4 |
Morgan Stanley
New York
|
-$449M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$419M |
ABBV Hedge Fund Activity: Q1 2026 in Review
4,115 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2026, worth a combined $282B — down 6.3% from $301B a quarter earlier.
Buyers outnumbered sellers: 192 funds opened new ABBV positions and 182 closed out — a net gain of 10 holders — while 1,735 added to existing stakes and 1,719 trimmed.
The largest buyer was Fisher Asset Management, adding an estimated $1.88B. The largest seller was Charles Schwab, cutting an estimated $2.71B.
- 4,115 institutional investors held AbbVie (ABBV) as of Q1 2026, down from 4,169 in Q4 2025.
- Funds reported $282B of AbbVie stock for Q1 2026, down 6.3% quarter-over-quarter.
- 192 funds opened new AbbVie positions in Q1 2026 and 182 closed out, a net change of +10 holders.
- The largest AbbVie buyer in Q1 2026 was Fisher Asset Management, an estimated $1.88B added.
- The largest AbbVie seller in Q1 2026 was Charles Schwab, an estimated $2.71B sold.
Based on aggregated 13F filings for Q1 2026.